CNTB

Connect Biopharma Holdings Ltd

Add to Watchlist

Advanced Chart

2.220

-0.13(-5.532%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.450

Open

2.350

VWAP

2.29

Vol

122.67K

Mkt Cap

123.35M

Low

2.1701

Amount

280.63K

EV/EBITDA(TTM)

Total Shares

55.10M

29.64M

EV/OCF(TTM)

P/S(TTM)

4.71

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

2 Analyst Rating

192.79% Upside

Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is 6.50 USD with a low forecast of 6.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

192.79% Upside

Current: 2.220

Low

6.00

Averages

6.50

High

7.00

192.79% Upside

Current: 2.220

Low

6.00

Averages

6.50

High

7.00

Northland

Outperform

initiated

$7.50

2025-07-22

New

Reason

Northland

Price Target

$7.50

2025-07-22

New

initiated

Outperform

Reason

Northland initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target.

Northland

Carl Byrnes

Outperform

initiated

$7.50

2025-07-22

New

Reason

Northland

Carl Byrnes

Price Target

$7.50

2025-07-22

New

initiated

Outperform

Reason

As previously reported, Northland analyst Carl Byrnes initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target. Lead candidate rademikibart is positioned as the first biologic for treating acute exacerbations in asthma and COPD, addressing "a major unmet need" and "poised to define a new therapeutic category," the analyst tells investors. Topline data from its Phase 2 studies is expected in the first half of 2026, notes the analyst, who sees peak sales potential exceeding $5B.

H.C. Wainwright

Brandon Folkes

initiated

2025-06-12

Reason

H.C. Wainwright

Brandon Folkes

Price Target

2025-06-12

initiated

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-04-01

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-03-31

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-03-31

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2024-09-06

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2024-09-06

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB.O) is -2.60, compared to its 5-year average forward P/E of -3.65. For a more detailed relative valuation and DCF analysis to assess Connect Biopharma Holdings Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.65

Current PE

-2.60

Overvalued PE

-0.29

Undervalued PE

-7.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.66

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.13

Undervalued EV/EBITDA

-9.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.28

Current PS

51.56

Overvalued PS

7.93

Undervalued PS

-3.37